Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Of The Impact Of AZD4017, A Selective 11bHSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia

Trial Profile

Phase II Study Of The Impact Of AZD4017, A Selective 11bHSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 4017 (Primary)
  • Indications Metabolic bone diseases
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2015 Accrual to date is 8%, according to United Kingdom Clinical Research Network record.
    • 28 May 2015 Status changed from not yet recruiting to recruiting as per United Kingdom Clinical Research Network.
    • 16 May 2015 Status changed from suspended to recruiting, as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top